Kiadis Pharma has raised EUR10m in a financing round to conduct Phase II study of a cell based medicinal product candidate, ATIR, and to prepare a Phase II/III study.
ATIR Phase II study is a confirmatory multi-center, proof-of-concept study. Kiadis Pharma CEO Manfred Ruediger said the support from existing and new investors attests to the clinical data generated for ATIR till date besides progress the company has achieved over a year.
“We are determined to advance ATIR in close cooperation with our clinical investigators in North America and Europe,” Ruediger added.
ATIR that received orphan drug status in the EU as well as the USA, is designed to allow stem cell transplantations from haploidentical donors to blood cancer sufferers.
When ATIR is administered as an adjunctive treatment along with haploidentical stem cell transplantation, early immune reconstitution is augmented without rooting Graft-versus-Host-Disease.
